About Us

A Laser Focus on Developing Curative Cancer Immunotherapies

TargaZyme is poised to revolutionize patient outcomes through our proprietary novel cancer immunotherapies. Our groundbreaking therapeutic solution addresses critical unmet medical challenges in cancer medicine, especially, with regard to enabling curative hematopoietic stem-cell transportation to become safer and more efficacious with TZ 101 and developing our next-generation Tumor Infiltrating Lympocyte (TIL) therapies i.e FucoTILs with the goal to transform survival for late-stage cancer patients with solid cancer tumors.

We are laser-focused on the development of our breakthrough proprietary cell therapies that use specialized immune cells from the patient or the donor to target/eliminate cancer cells regulate and treat inflammation and life-threatening side effects from standard-of-care cancer therapies. Powered by our innovative proprietary cell efficacy multiplier technology, our cancer immunotherapy drugs aim to simultaneously enable precise immune cell delivery to the disease sites as well as amplification of the innate power of the patient’s immune cells to effectively eradicate, cure and even prevent cancer. This approach has shown great promise in preclinical and clinical trials with successfully treating blood cancers, solid cancer tumors, autoimmune diseases, and regenerative medicine.

TargaZyme is an early pioneer of cellular therapy and has accumulated the experience of advancing a portfolio of innovative products, achieving regulatory milestones including a Phase 3 Special Protocol Assessment (SPA) award from the FDA, and obtaining multiple FDA orphan-drug designations and a BLA pathway that enables 12 years of protection from generic drugs. Targazyme has been awarded 27 worldwide patents with more than 10 patent applications pending. The technology has been validated through multiple independent peer-reviewed prestigious medical and scientific publications and receipt of $50M+ of notable medical and scientific awards for the advancement of the fucosylation platform technology. Furthermore, we have built strategic partnerships with leading cancer centers such as MD Anderson Cancer Center, Harvard, University of Pennsylvania Medical Center, Yale Medical Center, corporate partners such as Kyowa Hakko Kirin, VidaCord of Spain, ThermoFisher, AVID Bioscience, Aragen, George Clinical, and NIH/NCI.

As we continue to advance medical innovation, we remain committed to pushing the boundaries of what is possible to accomplish our mission. Our cutting-edge products represent a transformative approach that promises to deliver curative cell-based therapies ultimately to successfully treat, cure and even prevent cancer.